3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
4
Endocrine
4
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Multiple Myeloma
130
Neoplasms, Plasma Cell
16
Recurrence
14
Lymphoma
10
Neoplasms
9
Immunoglobulin Light-chain Amyloidosis
8
Monoclonal Gammopathy of Undetermined Significance
5
Leukemia, Plasma Cell
5
Hematologic Neoplasms
5
Waldenstrom Macroglobulinemia
3
Smoldering Multiple Myeloma
3
Paraproteinemias
3
Leukemia
3
Respiratory Aspiration
2
Ovarian Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Kidney Neoplasms
2
Hypoventilation
2
Gastrointestinal Neoplasms
2
Disease
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Breast Neoplasms
2
Amyloidosis
2
Venous Thromboembolism
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Taste Disorders
1
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Thyroid Carcinoma, Anaplastic
×
Plasma cell
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled